![Michael Lyle](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Michael Lyle
Director Técnico/Científico/I+D en Welichem Biotech, Inc. .
Cargos activos de Michael Lyle
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Welichem Biotech, Inc.
![]() Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | Director Técnico/Científico/I+D | 01/12/2009 | - |
Historial de carrera de Michael Lyle
Formación de Michael Lyle.
Simon Fraser University | Doctorate Degree |
Estadísticas
Internacional
Canadá | 3 |
Operativa
Chief Tech/Sci/R&D Officer | 1 |
Doctorate Degree | 1 |
Sectorial
Health Technology | 2 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Welichem Biotech, Inc.
![]() Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | Health Technology |
- Bolsa de valores
- Insiders
- Michael Lyle
- Experiencia